Moreover, the detection of BRCA1/2 gene mutations in breast and ovarian cancer with NGS technology could reduce the risk of death due to early detection of the diseases and extend the expected life expectancy leading to a total productivity gain (51 million baht) for breast (44 million baht) or ovarian (7 million baht) cancer patients. This evidence concerns the gene BRCA1 and ovarian cancer.